Patents by Inventor Guohuang Fan

Guohuang Fan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250179087
    Abstract: The present invention disclose novel compounds; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by LPAR5 by administering the compounds of the invention. In particular, the compounds of the invention may be used as LPAR5 inhibitors.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 5, 2025
    Inventors: Jianbei XI, Yue LI, Guohuang FAN, Jianfei WANG
  • Publication number: 20250034121
    Abstract: The disclosure relates to the compounds as GPR183 inhibitors, the methods for preparing these compounds, and the compositions and their uses as treatment or prevention of cancers, autoimmune diseases, pain, and osteoporosis using GPR 183 inhibitors targeted immune cells.
    Type: Application
    Filed: October 17, 2022
    Publication date: January 30, 2025
    Inventors: Jianbei Xi, Guohuang Fan, Jianfei Wang
  • Publication number: 20240352134
    Abstract: The present invention relates to anti-CCR8 antibodies and to methods of using anti-CCR8 antibodies. The anti-CCR8 antibodies described herein are useful for the diagnosis and treatment of diseases mediated by CCR8 and/or CCL1, such as various cancers and neuropathic pain associated with abnormal CCL1/CCR8 axis.
    Type: Application
    Filed: June 24, 2022
    Publication date: October 24, 2024
    Inventors: Guohuang Fan, Jianfei Wang, Juan DU, Na Wang
  • Publication number: 20240254113
    Abstract: Provided are compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as well as uses and methods for treating a disease mediated by CD38 by administering the compounds.
    Type: Application
    Filed: April 28, 2022
    Publication date: August 1, 2024
    Inventors: Jianbei Xi, Guohuang Fan, Jianfei Wang, Kin Chiu Fong
  • Patent number: 11884682
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: January 30, 2024
    Assignee: NANJING IMMUNOPHAGE BIOTECH CO., LTD.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang
  • Publication number: 20230159446
    Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
    Type: Application
    Filed: December 23, 2022
    Publication date: May 25, 2023
    Inventors: Guohuang FAN, Hongyu YANG, Kin Chiu FONG, Jianfei WANG
  • Publication number: 20230038589
    Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.
    Type: Application
    Filed: July 3, 2020
    Publication date: February 9, 2023
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Hongyu Yang, Kin Chiu Fong, Jianfei Wang
  • Publication number: 20220356247
    Abstract: The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer, chronic lymphocyte leukemia (CLL), and acute lymphocytic leukemia (ALL).
    Type: Application
    Filed: September 24, 2020
    Publication date: November 10, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO.,LTD.
    Inventors: Guohuang FAN, Jianfei WANG
  • Publication number: 20220356246
    Abstract: The present invention relates to anti-ROR1 antibodies and to methods of using anti-ROR1 antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases, such as various cancers, associated with aberrant expression of ROR1.
    Type: Application
    Filed: September 24, 2020
    Publication date: November 10, 2022
    Applicant: NANJING IMMUNOPHAGE BIOTECH CO.,LTD.
    Inventors: Guohuang FAN, Jianfei WANG
  • Publication number: 20210403484
    Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 30, 2021
    Applicant: Nanjing Immunophage BioTech Co., Ltd.
    Inventors: Guohuang Fan, Kin Chiu Fong, Hongyu Yang, Jianfei Wang